Literature DB >> 14632789

Effective treatment of hereditary haemochromatosis with desferrioxamine in selected cases.

Peter Nielsen1, Roland Fischer, Peter Buggisch, Gritta Janka-Schaub.   

Abstract

The treatment of iron overload by s.c. desferrioxamine (DFO) was studied in three patients with hereditary haemochromatosis in which phlebotomy treatment was not, or transiently not, possible because of their serious clinical condition or the lack of appropriate peripheral veins. Repeated non-invasive liver iron concentration measurements by superconducting quantum interference device biosusceptometry showed that DFO treatment (2 g/d for 9-11 months) was as effective (liver iron elimination rate: 12 mg/d) as normal phlebotomy treatment (5.9 or 14.3 mg/d respectively) with weekly 500-ml blood removals. This demonstrates that DFO is an effective alternative therapy for haemochromatosis when phlebotomy is not possible.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14632789     DOI: 10.1046/j.1365-2141.2003.04708.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  11 in total

1.  The diagnosis and management of hereditary haemochromatosis.

Authors:  Paul Clark; Laurence J Britton; Lawrie W Powell
Journal:  Clin Biochem Rev       Date:  2010-02

2.  [28-year old patient with successfully treated dilatative cardiomyopathy].

Authors:  E Burri; M Decker; U Eriksson; P Buser; L Hunziker
Journal:  Internist (Berl)       Date:  2008-03       Impact factor: 0.743

3.  The global burden of iron overload.

Authors:  Marnie J Wood; Richard Skoien; Lawrie W Powell
Journal:  Hepatol Int       Date:  2009-07-29       Impact factor: 6.047

4.  A patient with a rare cause of elevated troponin I.

Authors:  Antonios Kilias; Karin Klingel; Meinrad Gawaz; Ulrich Kramer; Peter Seizer
Journal:  Clin Res Cardiol       Date:  2015-04-28       Impact factor: 5.460

Review 5.  Revisiting the intersection of amyloid, pathologically modified tau and iron in Alzheimer's disease from a ferroptosis perspective.

Authors:  Paul J Derry; Muralidhar L Hegde; George R Jackson; Rakez Kayed; James M Tour; Ah-Lim Tsai; Thomas A Kent
Journal:  Prog Neurobiol       Date:  2019-10-08       Impact factor: 11.685

Review 6.  Molecular and clinical aspects of iron homeostasis: From anemia to hemochromatosis.

Authors:  Manfred Nairz; Günter Weiss
Journal:  Wien Klin Wochenschr       Date:  2006-08       Impact factor: 1.704

7.  A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis.

Authors:  Pradyumna Phatak; Pierre Brissot; Mark Wurster; Paul C Adams; Herbert L Bonkovsky; John Gross; Peter Malfertheiner; Gordon D McLaren; Claus Niederau; Alberto Piperno; Lawrie W Powell; Mark W Russo; Ulrich Stoelzel; Wolfgang Stremmel; Louis Griffel; Nicola Lynch; Yiyun Zhang; Antonello Pietrangelo
Journal:  Hepatology       Date:  2010-11       Impact factor: 17.425

Review 8.  Chelation therapy for iron overload.

Authors:  James C Barton
Journal:  Curr Gastroenterol Rep       Date:  2007-03

Review 9.  Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.

Authors:  Christina N Kontoghiorghe; George J Kontoghiorghes
Journal:  Drug Des Devel Ther       Date:  2016-01-29       Impact factor: 4.162

Review 10.  Hyperferritinemia-A Clinical Overview.

Authors:  Miriam Sandnes; Rune J Ulvik; Marta Vorland; Håkon Reikvam
Journal:  J Clin Med       Date:  2021-05-07       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.